Proteinuria due to increased dose of deferasirox in a pediatric patient with thalassemia major: case report
2018 ◽
Vol 5
(6)
◽
pp. 2338
◽
Keyword(s):
Deferasirox is an iron chelator that used in B-thalassemia in worldwide. Nephrotoxicity is one of the common side effects of the deferasirox. Nephrotoxicity can be seen in the form of nephritis and tubulopathy. A 6-year-old male whose ferritin levels were above 3500 ng/mL is reported in this article. Deferasirox was increased from 30 mg/kg/day to 40 mg/kg/day because of the high levels of ferritin. In complete urinalysis of the patient after 3 weeks later +3 protein was detected, and spot urine protein/creatinine ratio was 2.5. In patient without symptoms and findings, deferasirox was discontinued. In his follow-ups, no proteinuria was detected in the complete urinalysis at the second week after the drug treatment was discontinued.
2021 ◽
Keyword(s):
2020 ◽
Vol 149
(1)
◽
pp. 76-81
Keyword(s):
2018 ◽
Vol 36
(15_suppl)
◽
pp. e20042-e20042
2021 ◽
Vol 10
(7)
◽
pp. 2734
Keyword(s):
2019 ◽
Vol 58
(6)
◽
pp. e376-e377
Keyword(s):
2016 ◽
Vol 9
(9)
◽
pp. 1
◽
Keyword(s):